High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

Zhuang, Zhenli; Sun, Cuiling; Gong, Hui

doi:10.3892/etm.2019.8010

Cited by 8 publications

(8 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Yang et al (24) showed that miR-218 was significantly downregulated in lung cancer tissues and was associated with prognosis of patients with lung cancer. Zhuang et al (25) reported that serum levels of miR-484 could help screen patients for NSCLC with a high sensitivity and specificity using receiver operating curve analyses. In the present study, miR-92a was significantly upregulated in NSCLC tissues and cell lines, which suggested that miR-92a could potentially act as a new diagnostic marker and therapeutic target in NSCLC treatment.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑92a promotes non‑small cell lung cancer cell growth by targeting tumor suppressor gene FBXW7

Teng

Cheng

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Microrna (mirna/miR)-92a has been identified as being significantly downregulated in non-small cell lung cancer (NSCLC) tissues using a miRNA array. However, its biological function and molecular mechanisms in NSCLC have not been fully elucidated. The aim of the present study was to determine the role of miR-92a in NSCLC and the mechanisms by which it affects NSCLC cells. The expression levels of miR-92a in NSCLC tissues and cell lines were analyzed using reverse transcription-quantitative PCR. Cell viability and cell apoptosis were determined using an MTT assay and flow cytometry, respectively. It was observed that miR-92a was significantly upregulated in NSCLC tissues and cell lines. Inhibition of miR-92a significantly suppressed viability of NSCLC cells, with concomitant downregulation of key proliferative genes, such as proliferating cell nuclear antigen and Ki-67. miR-92a downregulation induced apoptosis of NSCLC cells, as evidenced by flow cytometry and apoptosis-related protein detection. Luciferase assays confirmed that miR-92a could directly bind to the 3'-untranslated region of tumor suppressor F-box/WD repeat-containing protein 7 (FBXW7) and suppress its translation. Furthermore, small interfering RNA-mediated FBXW7 inhibition partially attenuated the tumor suppressive effect of an miR-92a inhibitor on NSCLC cells. Collectively, these findings demonstrated that miR-92a might function as an oncogene in NSCLC by regulating FBXW7. In conclusion, miR-92a could serve as a potential therapeutic target in NSCLC treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑92a promotes non‑small cell lung cancer cell growth by targeting tumor suppressor gene FBXW7

Teng

Cheng

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Analysis of miR-484 revealed that it is involved in the regulation of angiogenic factors and its overexpression downregulates VEGFB and VEGFR2 expression; different levels of miR-484 may reflect the response to therapy [ 53 ]. High expression of miR-484 in the serum of patients with non-small cell lung cancer (NSCLC) was positively correlated with histological grade, lymph node metastasis, distant metastasis, clinical stage and poor overall survival [ 54 ]. In contrast, miR-484 is recommended as a suitable endogenous control for miRNA experiments [ 14 , 55 ].…”

Section: Discussionmentioning

confidence: 99%

Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study

Holubeková

Kolková

Grendár

et al. 2020

IJMS

View full text Add to dashboard Cite

MicroRNAs in the circulation of breast cancer (BC) patients have great potential for the early diagnosis, treatment and monitoring of breast cancer. The aim of this preliminary study was to obtain the expression profile of selected miRNAs in the plasma of BC patients that could discriminate BC patients from healthy volunteers and may be useful in early detection of BC. Significantly deregulated miRNAs were evaluated by pathway analysis with the prediction of potential miRNA targets. The study enrolled plasma samples from 65 BC patients and 34 healthy volunteers. Selected miRNAs were screened in pilot testing by the real-time PCR (qPCR) method, and the most appropriate reference genes were selected for normalisation by the geNorm algorithm. In the final testing, we detected miR-99a, miR-130a, miR-484 and miR-1260a (p < 0.05) as significantly up-regulated in the plasma of BC patients. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis revealed that all significantly deregulated miRNAs are involved in the Hippo and Transforming Growth Factor-beta (TGF-beta) signalling pathways. Our study confirmed a different profile of selected circulating miRNAs in the plasma of BC patients with an emphasis on some critical points in the analysis process.

show abstract

“…Recent studies have demonstrated that serum miR-484 is increased in patients with non-small cell lung carcinoma (NSCLC) [32] and that miR-484 promotes the progression of NSCLC [33], indicating that this miRNA may be involved in cancer progression. Thus, miR-484 may be involved in various pathological conditions other than EMTrelated disorders.…”

Section: Discussionmentioning

confidence: 99%

miR-484: A Possible Indicator of Drug-Induced Pulmonary Fibrosis

et al. 2020

View full text Add to dashboard Cite

Background: Drug-induced lung injury leads to serious lung diseases, such as pulmonary fibrosis. We demonstrated in an alveolar epithelial cell line A549/ABCA3 that certain microRNAs were associated with bleomycin induced epithelial-mesenchymal transition (EMT) which is closely related to pulmonary fibrosis. In this study, we focused on the role of miR-484 in drug-induced EMT using A549/ABCA3 cells and a mouse lung injury model. Methods: The expression of EMT-related genes and miR-484 was detected by real-time polymerase chain reaction. miR-484-targeted proteins were analyzed by Western blot. Pulmonary fibrosis mouse model was prepared by the intratracheal administration of BLM. As miR-484 is known to target SMAD2 and zinc finger E-box binding homeobox 1 (ZEB1), which are the well-known EMT-related transcription factors, we assessed the effects of a miR-484 inhibitor or mimic on the mRNA/protein expression of both the factors. Results: We found that bleomycin significantly suppressed the intracellular expression and extracellular release of miR-484 in A549/ABCA3 cells. Moreover, the miR-484 mimic and inhibitor showed no drastic effects on the expression of the EMT-related transcription factors. In addition, the miR-484 mimic had no effect on the bleomycin-induced altered mRNA expression of the α-smooth muscle actin, a representative EMT marker. This suggested that miR-484 did not directly contribute to bleomycin-induced EMT in A549/ABCA3 cells. In contrast, the significant decrease in miR-484 expression in the lung tissue or plasma of bleomycin-administered mice suggested that miR-484 expression was closely correlated with bleomycin-induced lung injury. Conclusions: These findings indicate that miR-484 could be a novel diagnostic indicator for drug-induced pulmonary fibrosis.

show abstract

High serum miR‑484 expression is associated with the diagnosis and prognosis of patients with non‑small cell lung cancer

Cited by 8 publications

References 28 publications

MicroRNA‑92a promotes non‑small cell lung cancer cell growth by targeting tumor suppressor gene FBXW7

MicroRNA‑92a promotes non‑small cell lung cancer cell growth by targeting tumor suppressor gene FBXW7

Pathway Analysis of Selected Circulating miRNAs in Plasma of Breast Cancer Patients: A Preliminary Study

miR-484: A Possible Indicator of Drug-Induced Pulmonary Fibrosis

Contact Info

Product

Resources

About